Streetbeat News

Products Services

ADCT

ADC Therapeutics has voluntarily paused enrollment in its Phase 2 LOTIS-9 trial of Zynlonta (Loncastuximab Tesirine-lpyl) and Rituximab (Lonca-r) in unfit or frail patients with previously untreated Diffuse Large B-Cell Lymphoma.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 11:05 am

SYBX

The FDA has granted Fast Track designation to Synlogic's labafenogene marselecobac (previously known as SYNB1934) for Phenylketonuria. This will expedite the review process for the drug, potentially leading to quicker market entry.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 11:03 am

BMY

Bristol Myers Squibb announced that a sub-study of its Phase 3 CheckMate-901 trial met its dual primary endpoints of overall survival and progression-free survival. The study showed that Opdivo in combination with cisplatin-based chemotherapy followed by Opdivo monotherapy demonstrated significant benefits compared to standard-of-care cisplatin-based combinations for patients with unresectable or metastatic urothelial carcinoma.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 11:01 am

NNVC

NanoViricides has reported that its antiviral clinical drug candidate, NV-387, has shown effectiveness in an animal model of lethal lung infection with Respiratory Syncytial Virus.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 10:50 am

TSM

Taiwan Semiconductor Manufacturing Company (TSMC) is set to begin construction of its second factory in Kumamoto in April next year. The factory will start production of 12-nano semiconductors in 2026.

Portfolio Pulse from Charles Gross

July 11, 2023 | 10:12 am

IMRN

Immuron Limited, an Australian biopharmaceutical company listed on NASDAQ as IMRN, has announced that its subsidiary, Ateria Health Australia, has launched Juvia in Australia. Immuron holds a 17.5% shareholding in Ateria, a UK-based biotech company that develops and distributes health supplements.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 10:06 am

VANI

Vivani Medical, Inc. (NASDAQ:VANI) announced that its subsidiary Cortigent, Inc. has completed the fifth year of its Early Feasibility Study (EFS) of profoundly blind patients implanted with the Orion® Visual Cortical Prosthesis System. The study, funded by the National Institutes of Health, reported no device malfunctions and a single serious adverse event which resolved quickly and resulted in no permanent harm.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 10:03 am

ZFOX

Cyware, a leading provider of threat intelligence management, security collaboration, and cyber fusion solutions, has expanded its partnership with ZeroFox (NASDAQ:ZFOX), an enterprise software-as-a-service leader in external cybersecurity. ZeroFox has been added to the Cyware Partner Advisory Marketplace, making its threat advisories available to Cyware customers.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 10:01 am

LYV

Sales for Taylor Swift's Eras Tour in Paris have been halted on Ticketmaster. The article may mention Live Nation Entertainment, Inc. (LYV).

Portfolio Pulse from Charles Gross

July 11, 2023 | 10:00 am

FB

Axios has reported that Meta Platforms Inc. is planning to introduce branded content tools to its Threads application. The move is aimed at enhancing the monetization capabilities of the platform.

Portfolio Pulse from Charles Gross

July 11, 2023 | 9:38 am